{"id":13846,"date":"2019-08-19T13:38:01","date_gmt":"2019-08-19T17:38:01","guid":{"rendered":"https:\/\/medicarereport.org\/?p=13846"},"modified":"2019-08-19T13:38:01","modified_gmt":"2019-08-19T17:38:01","slug":"roche-prices-cancer-drug-at-17k-a-month","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=13846","title":{"rendered":"Roche prices cancer drug at $17K a month"},"content":{"rendered":"<p>(By Alia Paavola for <em>Becker&#8217;s Hospital Review<\/em>)<\/p>\n<p>Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half the cost of a similar drug sold by Eli Lilly and Bayer, according to\u00a0STAT.\u00a0 Continue reading <a href=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/roche-prices-cancer-drug-at-17k-a-month.html\">article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-7859\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-300x200.jpg\" alt=\"\" width=\"300\" height=\"200\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-300x200.jpg 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-768x512.jpg 768w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo-1024x682.jpg 1024w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/7227528-Syringes-and-needles-Stock-Photo.jpg 1300w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Alia Paavola for Becker&#8217;s Hospital Review) Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-13846","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13846"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13846\/revisions"}],"predecessor-version":[{"id":13847,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/13846\/revisions\/13847"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}